ADAPY (Adaptimmune Therapeutics) Cyclically Adjusted FCF per Share: $-0.91 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Cyclically Adjusted FCF per Share?

Adaptimmune Therapeutics ADAPY +5.80% Cyclically Adjusted FCF per Share is $-0.91 as of Jun. 2025.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Adaptimmune Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2025 was $-0.132. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.91 for the trailing ten years ended in Jun. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-26), Adaptimmune Therapeutics's current stock price is $0.02645. Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2025 was $-0.91. Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Adaptimmune Therapeutics  (OTCPK:ADAPY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Related Terms


Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.93 -0.89

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.89 -0.89 -0.91 -0.91

ADAPY vs BCLI, APRE, JSPR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adaptimmune Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=-0.132/138.4000*138.4000
=-0.132

Current CPI (Jun. 2025) = 138.4000.

Adaptimmune Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201509 0.000 100.200 0.000
201512 0.000 100.400 0.000
201603 -0.300 100.400 -0.414
201606 -0.250 101.000 -0.343
201609 -0.247 101.500 -0.337
201612 -0.064 102.200 -0.087
201703 -0.572 102.700 -0.771
201706 -0.291 103.500 -0.389
201709 0.127 104.300 0.169
201712 -0.249 105.000 -0.328
201803 -0.525 105.100 -0.691
201806 -0.389 105.900 -0.508
201809 0.083 106.600 0.108
201812 -0.311 107.100 -0.402
201903 -0.357 107.000 -0.462
201906 -0.335 107.900 -0.430
201909 -0.285 108.400 -0.364
201912 -0.125 108.500 -0.159
202003 0.134 108.600 0.171
202006 -0.186 108.800 -0.237
202009 -0.111 109.200 -0.141
202012 -0.197 109.400 -0.249
202103 -0.308 109.700 -0.389
202106 -0.213 111.400 -0.265
202109 -0.300 112.400 -0.369
202112 0.831 114.700 1.003
202203 -0.393 116.500 -0.467
202206 -0.313 120.500 -0.359
202209 -0.357 122.300 -0.404
202212 -0.008 125.300 -0.009
202303 -0.239 126.800 -0.261
202306 -0.244 129.400 -0.261
202309 -0.201 130.100 -0.214
202312 -0.068 130.500 -0.072
202403 -0.134 131.600 -0.141
202406 0.179 133.000 0.186
202409 -0.215 133.500 -0.223
202412 -0.138 135.100 -0.141
202503 -0.264 136.100 -0.268
202506 -0.132 138.400 -0.132

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.91 mean?
Adaptimmune Therapeutics (ADAPY) has a Cyclically Adjusted FCF per Share of $-0.91 as of Jun. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Cyclically Adjusted FCF per Share too high?
Adaptimmune Therapeutics' current Cyclically Adjusted FCF per Share is $-0.91.
How does Adaptimmune Therapeutics' Cyclically Adjusted FCF per Share compare to BCLI and APRE?
Adaptimmune Therapeutics' Cyclically Adjusted FCF per Share of $-0.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Cyclically Adjusted FCF per Share is $-0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Cyclically Adjusted FCF per Share of $-0.91. The current Cyclically Adjusted FCF per Share is $-0.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Cyclically Adjusted FCF per Share is $-0.91 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].